Syndax Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
48.27 |
126.18 |
273.10 |
459.95 |
646.02 |
804.11 |
| Przychód Δ r/r |
0.00% |
161.40% |
116.43% |
68.42% |
40.45% |
24.47% |
| Przychód (min) |
22.86 |
82.22 |
224.37 |
442.51 |
486.10 |
605.05 |
| Przychód (max) |
134.33 |
151.15 |
408.34 |
477.40 |
890.14 |
1,107.97 |
| EBITDA (średnia) |
1.89 |
4.93 |
10.67 |
17.96 |
25.23 |
31.40 |
| EBIT (średnia) |
1.85 |
4.85 |
10.49 |
17.66 |
24.81 |
30.88 |
| EBIT % |
3.84% |
3.84% |
3.84% |
3.84% |
3.84% |
3.84% |
| Zysk netto (średni) |
-277.66 |
-327.57 |
-247.23 |
-143.81 |
-112.31 |
31.28 |
| Zysk netto % |
-575.18% |
-259.60% |
-90.53% |
-31.27% |
-17.39% |
3.89% |
| EPS (średnia) |
-3.48 |
-3.83 |
-2.75 |
-1.57 |
-1.31 |
0.37 |
| Liczba analityków (Przychody) |
10 |
8 |
11 |
9 |
3 |
4 |
| Liczba analityków (EPS) |
10 |
9 |
10 |
7 |
5 |
2 |
| symbol |
SNDX |
SNDX |
SNDX |
SNDX |
SNDX |
SNDX |